LISBON, Portugal -
- Choosing a More Appropriate Route of Administration for Fast Acting Pain Relief Could be the key to Improvement
The first results of the first European survey of cancer patients’ experience of breakthrough pain[1] were presented today at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC).
(Logo:
Previous surveys have looked at the overall management of pain in cancer patients but this is the first international study to look in detail at Breakthrough Cancer Pain (BTCP) from a patient perspective. These results for the first 200 patients from the UK, Sweden and Denmark offer valuable insight into cancer patients’ experiences with breakthrough pain management and the impact of the condition on their daily lives.
- On average each patient had 3 episodes of BTCP per day - Each episode had an average duration of 60 minutes - 96% of the pain episodes were described as moderate to severe - For 87% of patients their BTCP interfered with their daily living including their ability to sleep, walk and get on with other people
“The study documents that breakthrough pain has a significant impact on cancer patients’ daily lives,” explained Dr. Andrew Davies, Department of Palliative Medicine, Royal Marsden Hospital, UK and the principal investigator of this survey. “Breakthrough pain is very different to background pain. Background pain is a continuous, chronic pain requiring around-the-clock medication. Breakthrough pain is a fast onset, short duration, intense pain that breaks through the chronic pain even when this is being controlled with medication. It is incapacitating and very distressing to the patient.”
For this kind of pain episode the ideal treatment would be fast acting with short duration of action to most closely match the nature of BTCP episodes. Moreover, it must be easy to use to improve patient compliance. However, the results of the survey show that:
- 98% of patients were using orally administered drugs - The time to first noticing a reduction in pain was on average 20 minutes - The time to knowing that the pain medication was really making a difference was on average 30 minutes or half way through the typical BTCP episode observed in this survey
“Oral opioids are still commonly used to manage BTCP despite the fact that the way these drugs work does not match the characteristics of a BTCP episode. Opioids given by other routes, for example intranasal, have significant advantages over oral opioids and the interim results from this survey suggest that these routes would be suitable for and welcomed by the majority of cancer patients with breakthrough pain,” said Dr. Andrew Davies.
The European Survey of Breakthrough Cancer Pain is continuing to recruit patients in Germany and Ireland and will expand into Austria, Belgium, Czech Republic, Finland, France, Greece, the Netherlands, Norway, Portugal, Spain and Switzerland to provide health care professionals across Europe with patient insights on the management of breakthrough cancer pain.
About Nycomed
Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio. Its R&D is built to be open for partnerships as in-licensing is a cornerstone in the company’s growth strategy.
Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed will further strengthen its position in key Asian markets.
Headquartered in Zurich, Switzerland, the company generated in 2008 total sales of EUR 3.4 billion and an adjusted EBITDA of EUR 1.2 billion.
For more information please visit www.nycomed.com
References
1. Davies A et al. European survey of oncology patient’s experience of breakthrough cancer pain: UK, SE and DK results. Poster presented at EFIC 2009.
About the survey
- First phase of an ongoing, multicentre observational study - First five countries include: UK, Sweden, Denmark, Germany, Ireland - 11 palliative care units - 400 patients with breakthrough cancer pain - Data collected on breakthrough cancer pain and treatment of breakthrough cancer pain - First results are based on 200 patients from UK (80), Sweden (80) and Denmark (40) - The study is supported by an educational grant from Nycomed.
For further information:
Media: Ulf Jonson, Senior International Brand Manager, Nycomed: +45-46-77-10-78
Source: Nycomed
For further information: Media: Ulf Jonson, Senior International Brand Manager, Nycomed:
+45-46-77-10-78
Related Press Releases
Instanyl(R) (intranasal fentanyl spray) Sets New Standard in Management of Breakthrough Cancer PainSeptember 10th, 2009 LISBON, Portugal -
- Head to Head Study Confirms Superiority of the New Intranasal Treatment for Breakthrough Cancer Pain Over OTFC
New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer.
New Research Indicates 95% of Patients are in Moderate to Severe Chronic Pain Despite One Year of TreatmentSeptember 9th, 2009 EUROPEAN FEDERATION OF CHAPTERS OF THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF PAIN (EFIC) CONGRESS, LISBON -
- Year-Long Tracking Survey Demonstrates That 19% Feel That Their Pain has Become Worse
95% of patients are suffering from moderate to severe chronic pain after one year of treatment[1] and only 12% are being prescribed strong opioids, according to a year-long survey presented today at the EFIC congress. The research reveals that more than half of patients' pain levels fail to improve over the course of a year's treatment and for 19%, their pain has become worse.
/C O R R E C T I O N -- Nycomed/September 8th, 2009 LISBON, Portugal - In the news release, "First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain" issued on 9 Sep 2009 07:00 GMT, by Nycomed over PR Newswire, we are advised by a representative of the company that the first set of bullet points should read "The median number of BTCP episodes per patient per day was 3; Each episode had a median duration of 60 minutes; 96% of the pain episodes were described as moderate to severe; For 90% of patients their BTCP interfered with their daily living including their ability to sleep, walk and get on with other people" and the second set of bullet points should read "At least 95% of patients were using orally administered drugs; "The time to first noticing a reduction in pain had a median time of 20 minutes; In this survey the median time to peak effect of the current BTCP rescue medications was 30 minutes". In addition, the fourth paragraph should read "For this kind of pain episode the ideal treatment would be fast acting with a short duration of action to most closely match the nature of BTCP episodes" instead of "For this kind of pain episode the ideal treatment would be fast acting with short duration of action to most closely match the nature of BTCP episodes" as incorrectly transmitted by PR Newswire.
A Fifth of People With MDS (Blood Cancer) Die Prematurely Because the NHS Won't Fund New Life-extending DrugsSeptember 2nd, 2009 LONDON -
- More Than Half of Blood Cancer Experts (56 Percent) say Less Priority is Given to Rarer Cancers Compared to Other Common Cancers
The results of a new survey, launched today by the UK MDS Patient Support Group, shows that almost a fifth (18 percent) of patients suffering from myelodysplastic syndromes (MDS) - a type of blood cancer - could have lived for longer if they had been able to access treatments that are currently not approved by NICE for treatment on the NHS.[1]
Furthermore, the survey revealed that more than half (56 percent) of blood cancer experts surveyed believe that less priority is given to rarer cancers versus other common cancers. [1]
David Hall, Chairman of MDS UK Patient Support Group, comments: "These results are alarming and distressing.
Approval of Instanyl(R) Marks Important Turn in Management of Breakthrough Cancer PainJuly 23rd, 2009 TAASTRUP, Denmark -
- First Intranasal Treatment for Breakthrough Cancer Pain Allowing Patients Fast, Effective and Good Tolerated Pain Relief Soon to be Available
Nycomed today announced that the European Commission has granted marketing authorisation for Instanyl, its first-in-class intranasal fentanyl spray designed to closely match the typical episodes of breakthrough cancer pain. "We have had a great unmet need in the management of breakthrough cancer pain.
New Survey Shows Seven Out of Ten Women Were too Embarrassed to Discuss Vaginal Dryness and Pain With Their PhysicianMay 17th, 2009 LONDON - The majority of post-menopausal women are uncomfortable talking about vaginal dryness and pain and are reluctant to seek medical help, according to results from a new international survey presented today at the European Congress on Menopause in London. Results from the survey show that over a third (39 percent) of post-menopausal women experience these symptoms of vaginal atrophy and 40 percent of women who have recently experienced vaginal dryness and pain said it interferes with their sex life, yet seven out of ten would not discuss the problem with their physician (only 30 percent of women would consider talking to a gynaecologist, and only 29 percent would consider talking to a GP).
Archimedes Pharma Announces Ground Breaking Phase III Data Showing NasalFent to be Superior to the Standard of Care for Breakthrough Cancer PainMay 7th, 2009 READING, England - Meets Primary Efficacy Endpoint
- First Study of a Next Generation Fentanyl Based Product to Show Superiority Over Immediate Release Morphine
Archimedes Pharma Limited, the UK based, pan-European specialty pharmaceutical company, today announces new positive headline phase III results for NasalFent(R), the Company's innovative and highly differentiated fentanyl citrate nasal spray, developed for the rapid relief of breakthrough cancer pain. The ground breaking phase III study compared NasalFent to immediate release morphine sulphate, the most commonly prescribed medicine for breakthrough cancer pain.
Archimedes Pharma Announces Ground-Breaking Phase III Data Showing NasalFent to be Superior to the Standard of Care for Breakthrough Cancer PainMay 7th, 2009 READING, England - Meets Primary Efficacy Endpoint
- First Study of a Next-Generation Fentanyl-Based Product to Show Superiority Over Immediate Release Morphine
Archimedes Pharma Limited, the UK-based, pan-European specialty pharmaceutical company, today announces new positive headline phase III results for NasalFent(R), the Company's innovative and highly differentiated fentanyl citrate nasal spray, developed for the rapid relief of breakthrough cancer pain. The ground breaking phase III study compared NasalFent to immediate release morphine sulphate, the most commonly prescribed medicine for breakthrough cancer pain.
EAU Position Statement on Screening for Prostate CancerApril 15th, 2009 ARNHEM, The Netherlands - The European Association of Urology (EAU) has taken into consideration the recent scientific information on randomised screening studies on prostate cancer (Schröder et al, NEJM 2009). Based on the results of the European Randomised Study for Screening of Prostate Cancer (ERSPC), the EAU has formulated a position statement regarding prostate cancer screening in Europe, and the subsequent actions to be taken by health professionals and health authorities.
FIRMAGON(R) (Degarelix) is Launched in Europe for the Treatment of Advanced Prostate CancerMarch 17th, 2009 STOCKHOLM, Sweden - Today marks the European launch of FIRMAGON(R) (degarelix), a new
treatment option in hormonal therapy for prostate cancer, with details
presented at the 24th Annual European Association of Urology (EAU) Congress
in Stockholm. FIRMAGON(R) is a new GnRH receptor blocker indicated for the
treatment of patients with advanced hormone-dependent prostate cancer.
Related News
7 out of 10 women too embarrassed to discuss vaginal drynessMay 19th, 2009 LONDON - Most post-menopausal women are uncomfortable talking about vaginal dryness and pain or reluctant to seek medical help, according to an international survey. Results from the survey show that over a third (39 percent) of such women experience these symptoms of vaginal atrophy and 40 percent of women who have recently experienced vaginal dryness and pain said it interferes with their sex life.
World's first patient implanted with smallest rechargeable neurostimulator completes one yearSeptember 12th, 2009 WASHINGTON - The world's first patient to have been implanted with the smallest ever neurostimulator for chronic pain is celebrating the one-year anniversary of his procedure today. One year ago, former U.S.
I am glad Jade is out of pain: ShilpaMarch 23rd, 2009 NEW DELHI - Bollywood star Shilpa Shetty is 'deeply saddened' by the death of her foe-turned-friend Jade Goody, but is 'glad' that the British reality TV star is now 'out of pain' after suffering from cancer. Goody, 27, passed away in her sleep at 3.14 a.m.
Chinese men willing to wear high-heeled shoes to experience ladyloves' painMarch 12th, 2009 NEW DELHI - Most Chinese men are willing to try high-heeled shoes to experience the pain their ladyloves often feel, according to a survey. The survey at a leading Chinese website was conducted to coincide with International Women's Day on March 8.
Analgesics abuse, addiction less common than suspectedJanuary 18th, 2009 TORONTO - Abuse and addiction to opioid analgesics, prescribed for chronic pain, is less common than suspected, according to the latest research. In a review study for pain treatment topics, editor of Pain-Topics.org, Stewart B.
Goody's hubby rushes to her bedside after 'emergency'March 14th, 2009 LONDON - Jade Goody's hubby hastened to her bedside after "an emergency" that saw his cancer-stricken wife in excruciating pain. Officials lifted the curfew on jailbird Jack Tweed after a nurse called for him as his terminally ill wife, who has been given few weeks to live after being diagnosed with cervical cancer, lay in pain.
Goldfish feel pain tooApril 26th, 2009 LONDON - A team of researchers has claimed to have solved the mystery that intrigued the science world for decades: Whether or not fish feel pain?
And, the answer is yes. Just like humans, goldfish feel pain too.
Like humans, goldfish too feel painMay 1st, 2009 LONDON - A team of researchers has claimed to have solved the mystery that intrigued the science world for decades: Whether or not fish feel pain?
And, the answer is yes. Just like humans, goldfish feel pain too.
Goody wants to carry on with TV showJanuary 22nd, 2009 LONDON - Reality show star Jade Goody is keen on continuing with the TV show she's on, though producers fear for her health. According to thesun.co.uk, executives of the show 'Living TV' are concerned that the pressure will be too much for her as she battles cervical cancer.
Jade Goody may die on reality television showFebruary 14th, 2009 LONDON - British reality TV star Jade Goody says she may allow her death to be filmed for a reality show. 'I've lived my whole adult life talking about my life.
